The role of rituximab and chemotherapy in aggressive B-cell lymphoma: A preliminary report of dose-adjusted EPOCH-R

被引：80

作者：

Wilson, WH

Gutierrez, M

O'Connor, P

Frankel, S

Jaffe, E

Chabner, BA

Grossbard, ML

机构：

[1] NCI, Ctr Canc Res, Bethesda, MD 20892 USA

[2] Massachusetts Gen Hosp, Dept Oncol, Boston, MA 02114 USA

[3] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA

[4] St Lukes Roosevelt Hosp, Dept Oncol, New York, NY USA

来源：

SEMINARS IN ONCOLOGY | 2002年 / 29卷 / 01期

关键词：

D O I：

10.1053/sonc.2002.30151

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

引用

页码：41 / 47

页数：7

共 37 条

[1]

Bates SE, 1996, ONCOLOGIST, V1, P269

[2]

Coiffier B, 1998, BLOOD, V92, P1927

[3]

Coiffier B, 2000, BLOOD, V96, p223A

[4]

BONE-MARROW INVOLVEMENT BY NON-HODGKINS-LYMPHOMA - THE CLINICAL-SIGNIFICANCE OF MORPHOLOGICAL DISCORDANCE BETWEEN THE LYMPH-NODE AND BONE-MARROW [J].

CONLAN, MG ;

BAST, M ;

ARMITAGE, JO ;

WEISENBURGER, DD .

JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (07) :1163-1172

[5]

Modulation of multidrug resistance (MDR) in hematological malignancies [J].

Covelli, A .

ANNALS OF ONCOLOGY, 1999, 10 :53-59

[6]

DEANS JP, 1993, J IMMUNOL, V151, P4494

[7]

Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs [J].

Demidem, A ;

Lam, T ;

Alas, S ;

Hariharan, K ;

Hanna, N ;

Bonavida, B .

CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1997, 12 (03) :177-186

[8]

p53 and chemosensitivity [J].

Ferreira, CG ;

Tolis, C ;

Giaccone, G .

ANNALS OF ONCOLOGY, 1999, 10 (09) :1011-1021

[9]

COMPARISON OF A STANDARD REGIMEN (CHOP) WITH 3 INTENSIVE CHEMOTHERAPY REGIMENS FOR ADVANCED NON-HODGKINS-LYMPHOMA [J].

FISHER, RI ;

GAYNOR, ER ;

DAHLBERG, S ;

OKEN, MM ;

GROGAN, TM ;

MIZE, EM ;

GLICK, JH ;

COLTMAN, CA ;

MILLER, TP .

NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (14) :1002-1006

[10]

GOLDIE JH, 1979, CANCER TREAT REP, V63, P1727

← 1 2 3 4 →